Skip to main content

Table 1 Randomized controlled trials of thiazides in the prevention of recurrent nephrolithiasis

From: Efficacy of standard and low dose hydrochlorothiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double-blind placebo-controlled trial

Author, Year Treatment, Dose Allocation Concealment Blinding Intention-to-treat Analysis Withdrawals described Selection for Hypercalciuria Follow-Up (Years) Treated/ Placebo, n/N Events/Total, n/N Thiazide Events/Total, n/N
Placebo
RR c Recurrence Outcome
Brocks, 1981 [29] Bendroflumethiazide, 2.5 mg TID a Unclear Double-blind No No No 1.6 33/29 5/33 5/29 NS Composite
Scholz, 1982 [31] HCTZ, 25 mg BID b Unclear Double-blind No No No 1 25/26 6/25 6/26 NS Symptomatic
Laerum, 1984 [23] HCTZ, 25 mg BID Unclear Double-blind Yes Yes No 3 23/25 5/23 12/25 0.45 Composite
Wilson, 1984 [26] HCTZ, 100 mg daily Unclear Open-label No No No 2.8 23/21 0.15 stones/year 0.32 stones/year 0.48 Symptomatic
Robertson, 1985 [27] Bendroflumethazide, 2.5 mg TID Unclear Open-label No No No 3–5 13/9 0.22 stones/year 0.58 stones/year 0.38 Symptomatic
Mortensen, 1986 [24] Bendroflumethazide, 2.5 mg Unclear Double-blind No No No 2 12/10 0/12 4/10 Composite
Ettinger, 1988 [22] Chlorthalidone, 25 m /50 mg Adequate Double-blind No Yes No 3 19/23/31 (25 mg /50 mg/placebo) 6/42 14/31 0.32 Composite
Ohkawa, 1992 [25] Trichlormethiazide, 4 mg Unclear Open-label No No Yes 2.14–2.21 82/93 24/82 57/93 0.42 Composite
Borghi, 1993 [21] Indapamide, 2.5 mg daily Unclear Open-label No Yes Yes 3 25/25 3/25 9/25 0.33 Composite
Ahlstrand, 1996 [30] HCTZ, 25 mg BID Unclear Open-label Yes Yes Yes 3.6–4.3 17/22 9/17 19/22 0.61 Composite
Fernandez-Rodriguez, 2006 [28] HCTZ, 50 mg daily Unclear None stated Yes No withdrawals No 3 50/50 16/50 28/50 0.57 Composite
  1. aTID, three times daily, b BID, twice times daily, c RR, relative risk